These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18066033)

  • 1. Antivirals--an increasingly healthy investment.
    McCarthy B
    Nat Biotechnol; 2007 Dec; 25(12):1390-3. PubMed ID: 18066033
    [No Abstract]   [Full Text] [Related]  

  • 2. Antivirals become a broader enterprise.
    Fox JL
    Nat Biotechnol; 2007 Dec; 25(12):1395-402. PubMed ID: 18066034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 4. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 5. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 6. Investment indicators show US is still ahead.
    Lähteenmäki R; Hodgson J
    Nat Biotechnol; 1998 Feb; 16(2):149-50. PubMed ID: 9487519
    [No Abstract]   [Full Text] [Related]  

  • 7. There's still gold in them thar pills.
    O'Reilly B
    Fortune; 2001 Jul; 144(2):58-62, 66-8, 70. PubMed ID: 11471355
    [No Abstract]   [Full Text] [Related]  

  • 8. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fight against COVID-19: market overview and pipeline of ongoing trials].
    Pontremoli R; Richard G; Vuddamalay G; Groux N
    Med Sci (Paris); 2020 Dec; 36(12):1225-1232. PubMed ID: 33211647
    [No Abstract]   [Full Text] [Related]  

  • 11. Handle with care.
    Macilwain C
    Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
    [No Abstract]   [Full Text] [Related]  

  • 12. Extensive consolidations continue in drug industry.
    Scott L
    Mod Healthc; 1994 Sep; 24(36):12. PubMed ID: 10136392
    [No Abstract]   [Full Text] [Related]  

  • 13. American Home bids $8.5 billion to buy New Jersey drug company.
    Scott L
    Mod Healthc; 1994 Aug; 24(32):12. PubMed ID: 10135368
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth in R&D investment holding up.
    Chipman A
    Nature; 2009 Nov; 462(7271):264. PubMed ID: 19924181
    [No Abstract]   [Full Text] [Related]  

  • 15. Silent running: the race to the clinic.
    Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract]   [Full Text] [Related]  

  • 16. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 17. Centacor stock dips again after articles on Centoxin.
    Wagner M
    Mod Healthc; 1992 Apr; 22(17):20. PubMed ID: 10117574
    [No Abstract]   [Full Text] [Related]  

  • 18. Patentability issues surrounding antivirals.
    Lu DL; Collison AM; Kowalski TJ
    Nat Biotechnol; 2007 Dec; 25(12):1403-4. PubMed ID: 18066035
    [No Abstract]   [Full Text] [Related]  

  • 19. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 20. New antivirals and drug resistance.
    Colman PM
    Annu Rev Biochem; 2009; 78():95-118. PubMed ID: 19254207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.